News Releases Year: - Any -202020192018201720162015201420132012 Items per page 102550 10/30/19 Summary ToggleClearside Biomedical to Report Third Quarter 2019 Financial Results and Provide Corporate Update on Wednesday, November 6, 2019 PDF Version 10/30/19 Summary ToggleClearside Biomedical Announces Option Exercise by REGENXBIO for Global License for Use of SCS Microinjector™ in AAV Gene Therapy Delivery PDF Version 10/23/19 Summary ToggleBausch Health Licenses Clearside Biomedical's XIPERE™ (Triamcinolone Acetonide Suprachoroidal Injectable Suspension), An Investigational Treatment For Macular Edema Associated With Uveitis PDF Version 10/17/19 Summary ToggleClearside Biomedical Suprachoroidal Injection Platform Featured in Multiple Presentations at the American Academy of Ophthalmology (AAO) 2019 Annual Meeting PDF Version 10/03/19 Summary ToggleClearside Biomedical Announces Multiple Presentations to be Given at the American Academy of Ophthalmology (AAO) 2019 Annual Meeting PDF Version 09/19/19 Summary ToggleClearside Biomedical Featured at Multiple European Scientific Retinal Congresses PDF Version 09/04/19 Summary ToggleREGENXBIO Announces Exclusive Worldwide Option and License Agreement with Clearside Biomedical for Evaluation of In-Office Delivery Platform for RGX-314 PDF Version 09/03/19 Summary ToggleClearside Biomedical to Present at the Janney Montgomery Scott Healthcare Conference PDF Version 08/22/19 Summary ToggleClearside Biomedical Provides New Drug Application Update for XIPEREᵀᴹ (triamcinolone acetonide suprachoroidal injectable suspension) PDF Version 08/07/19 Summary ToggleClearside Biomedical Announces Second Quarter 2019 Financial Results and Provides Corporate Update PDF Version Pagination First page First Previous page Page 2 Current page 3 Page 4 Page 5 Next page Last page Last
